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1. Introduction 
Type 1 diabetes mellitus (T1DM) is one of most frequent autoimmune diseases and is 
characterized by absolute or nothing short of absolute endogenous insulin deficiency which 
results in hyperglycemia that is considered to be a primary cause of diabetic complications 
(DC) (Rambhade et al., 2010). T1DM leads to various chronic micro- and macrovascular 
complications. Diabetic nephropathy is a major cause of morbidity and mortality in patients 
with DM. Microvascular disease is the main determinant in the development of late 
complications in DM. 
Persistent hyperglycemia is linked with glycation, glycoxidation, and oxidative stress 
(Aronson, 2008; Negre-Salvayre et al., 2009). During glycation and glycoxidation there are 
formed early, intermediate and advanced glycation products via Maillard reaction, glucose 
autoxidation and protein glycation. Accumulation of advanced glycation end products 
(AGEs) has several toxic effects and takes part in the development of DC, such as 
nephropathy (Kashihara et al, 2010), neuropathy, retinopathy and angiopathy (Peppa & 
Vlassara, 2005; Yamagishi et al., 2008; Goh & Cooper, 2008; Karasu, 2010). Higher plasma 
levels of AGEs are associated also with incident cardiovascular disease and all-cause 
mortality in T1DM (Nin et al., 2011). AGEs are believed to induce cellular oxidative stress 
through the interaction with specific cellular receptors (Ramasamy et al., 2005; Boulanger et 
al., 2006; Yamagishi, 2009; Mosquera, 2010). On the other side, carbonyl stress-induced 
tissue damage is caused by AGE precursors formed by hyperglycaemia, hyperlipidemia, 
nonenzymatic glycation, peroxidation of lipids and metabolic processes. 
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It has been suggested that the chronic hyperglycaemia in diabetes enhances the production 
of reactive oxygen species (ROS) from glucose autoxidation, protein glycation and 
glycoxidation, which leads to tissue damage (Son, 2007). Also, cumulative episodes of acute 
hyperglycaemia can be source of acute oxidative stress. A number of studies have 
summarized the relation between glycation and oxidation (Boyzel et al., 2010). The 
overproduction of ROS leads to oxidative modification of biologically important 
compounds and damage of them. Uncontrolled production of ROS often leads to damage of 
cellular macromolecules (DNA, lipids and proteins).  
Some oxidation products or lipid peroxidation products may bind to proteins and amplify 
glycoxidation-generated lesions. Lipid peroxidation of polyunsaturated fatty acids, one of 
the radical reaction in vivo, can adequately reflect increased oxidative stress in diabetes. 
Advanced oxidation protein products (AOPP) are formed during oxidative stress by the 
action of chlorinated oxidants, mainly hypochlorous acid and chloramines.  In diabetes the 
formation of AOPP is induced by intensified glycoxidation processes, oxidant-antioxidant 
imbalance, and coexisting inflammation (Piwowar, 2010a, 2010b). AOPP are supposed to be 
structurally similar to AGEs and to exert similar biological activities as AGEs, i.e. induction 
of proinflammatory cytokines in neutrophils, as well as in monocytes, and adhesive 
molecules (Yan et al., 2008). Accumulation of AOPP has been found in patients with chronic 
kidney disease (Bargnoux, et al., 2009). Further possible sources of oxidative stress are 
decreased antioxidant defenses, or alterations in enzymatic pathways. 
Diabetes is associated also with inflammation (Navaro & Mora, 2006; Wautier et al., 2006; 
Devaraj et al., 2007; Hartge et al., 2007; Fawaz, et al., 2009 ; Van Sickle et al., 2009; Nobécourt 
et al., 2010). ROS are implicated also in the pathogenesis of the inflammatory response to 
ischemic-reperfusion which is exacerbated in diabetes. Oxidative stress during reperfusion 
is markedly balanced in diabetes and this appears to results from increased leukocyte 
recruitment and a higher capacity of diabetic leukocytes to generate ROS in response to 
stimulation. Several adhesion molecules are expressed on endothelial cells and participate in 
leukocyte adhesion to the endothelium. These molecules are important for monocyte–
endothelium interaction in the initiation and progression of atherosclerosis. The monocyte-
macrophage is a pivotal cell in atherogenesis. Cellular adhesion molecules mediate 
attachment and transmigration of leukocytes across the endothelial surface and are thought 
to play a crucial role in the early steps of atherogenesis (Seckin et al., 2006). Adhesion 
molecule VCAM-1 is not expressed under baseline conditions but is rapidly induced by 
proatherosclerotic conditions in rabbits, mice, and humans, including in early lesions. 
Initially, it is unclear whether VCAM-1 is simply a marker for atherogenesis or whether it 
acts in this disease pathway. AGEs promote VCAM-1 expression and atheroma formation in 
rabbits (Vlassara et al., 1995) and in cultured human endothelial cells (Schmidt et al., 1995). 
These results suggest the involvement of AGEs in the accelerated coronary atherosclerosis 
on diabetes (Zhang et al., 2003). Plasma concentrations of VCAM-1 are elevated also in 
T1DM patients with microalbuminuria and overt nephropathy (Schmidt et al., 1996; Clausen 
et al, 2000). 
Diabetic nephropathy is characterized by specific morphological changes including 
glomerular basement membrane thickening, mesangial expansion and glomerular and 
tubulointersticial sclerosis. The first clinical manifestation of diabetic nephropathy is 
microalbuminuria, defined as a urinary albumin excretion rate of 20 to 200 microgram/min.  
Growth factor TGF-beta1 is one of profibrotic cytokines and is important mediator in the 
pathogenesis of diabetic nephropathy (Goldfarb & Ziyadeh, 2001; Schrijvers et al., 2004; 
Wang et al., 2005; Wolf & Ziyadeh, 2007). TGF-beta1 stimulates production of extracellular 
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matrix components such as collagen-IV, fibronectin, proteoglycans (decorin, biglycan). TGF-
beta1 may cause glomerulosclerosis and its one of the causal factor in myointimal 
hyperplasia after baloon injury of carotid artery. It mediates angiotensin-II modulator effect 
on smooth muscle cell growth. Besides profibrotic activity, TGF-beta1 has 
immunoregulatory function on adaptive immunity too. AGEs induce connective tissue 
growth factor-mediated renal fibrosis through TGF-beta1-independent Smad3 signalling 
(Zhou et al., 2004; Chung et al., 2010). 
The present study investigates the relationship between diabetes complications presence, 
diabetes control (represented by actual levels of HbA1c (HbA1cA) and mean of HbA1c 
during the last 2 years (HbA1cP)), early glycation products (fructosamine (FAM)), serum 
advanced glycation end products (s-AGEs), lipid peroxidation products (LPO), advanced 
oxidation protein products (AOPP), profibrotic cytokines and adhesive molecules in 
patients with T1DM. We wanted to find a relationship of DC to glycative and oxidative 
stress parameters, circulating (serum) TGF-beta1 and soluble VCAM-1. Further, we aimed to 
compare measured parameters in groups –DC, one with DR, with DR combined with 
another DC and one with only DC another than DR and their combinations. The further aim 
of the present study was to evaluate if monitoring of circulating FAM, HbA1c, s-AGEs, 
AOPP, LPO in patients with T1DM could be useful to predict the diabetic complications 
development. 
2. Study design and methods 
2.1 Patients and design 
The studied group consisted of 46 children and adolescents with T1DM regularly attending 
the 1st Department of Pediatrics, Children Diabetological Center of the Slovak Republic, 
University Hospital, Faculty of Medicine, Comenius University, Bratislava. They had T1DM 
with duration at least for 5 years.  One of children was obese (BMIc 97 percentile) and three 
of them were of overweight (BMIc about 90 percentile). The file was divided into two 
subgroups: 20 persons without DC (-DC) and 46 those with them (+DC). Then the file of 
+DC patients  was divided into several subgroups according to particular complications: the 
patients only with retinopathy, those with neuropathy combined with another kinds of DC 
and those with other than retinopathy to compare the parameters of glycative and oxidative 
stress and cytokines in each mentioned subgroups. The urine samples in our patients were 
collected 3 times overnight, microalbuminuria was considered to be positive when UAER 
was between 20 and 200 microgram/min in 2 samples. No changes (fundus diabetic 
retinopathy) were found by the ophtalmologist examining the eyes in subject without 
retinopathy. Diabetic neuropathy was confirmed by EMG exploration using the 
conductivity assessment of sensor and motor fibres of peripheral nerves. The controls file 
consists of 26 healthy children. The samples of EDTA capillary blood were used to 
determine of HbA1c and serum samples were used to determine of FAM, s-AGEs, AOPP 
and VCAM-1. The samples of serum were stored in -18°C/-80°C.  
2.2 Parameter analysis  
2.2.1 Determination of UAER 
UAER was determined by means of immunoturbidimetric assay (Cobas Integra 400 Plus, 
Roche, Switzerland), using the commercial kit 400/400Plus. The assay was performed as a 
part of patients routine monitoring in Department of Laboratory Medicine, University 
Hospital, Bratislava. 
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2.2.2 Determination of fructosamine 
For the determination of fructosamine we used a kinetic, colorimetric assay and 
subsequently spectrophotometrical determination at wavelength 530 nm. We used 1-deoxy-
1-morpholino-fructose (DMF) as the standard. Serum samples were stored at -79°C and 
were defrost only once. This test is based on the ability of ketoamines to reduce nitroblue 
tetrazolium (NBT) to a formazan dye under alkaline conditions. The rate of formazan 
formation, measured at 530 nm, is directly proportional to the fructosamine concentration. 
Measurements were carried out in one block up to 5 samples. To 3 ml of 0.5 mmol/l NBT 
were added 150 microliters of serum and the mixture was incubated at 37°C for 10 minutes. 
The absorbance was measured after 10 min and 15 min of incubation at Novaspec analyzer 
II, Biotech (Germany). 
2.2.3 Determination of glycated hemoglobin HbA1c 
HbA1c was determined from EDTA capillary blood immediately after obtained by the low-
pressure liquid chromatography (LPLC) (DiaSTAT, USA) in conjunction with gradient 
elution. Before testing hemolysate is heated at 62-68°C to eliminate unstable fractions and 
after 5 minutes is introduced into the column. Hemoglobin species elute from the cation-
exchange column at different times, depending on their charge, with the application of 
buffers of increasing ionic strength. The concentration of hemoglobins is measured after 
elution from the column, which is then used to quantify HbA1c by calculating the area 
under each peak. Instrument calibration is always carried out when introducing a new 
column set procedure (Bio-RAD, Inc., 2003).  
2.2.4 Determination of serum AGEs 
Serum AGEs were determined as AGE-linked specific fluorescence, serum was diluted 20-
fold with deionized water, the fluorescence intensity was measured after excitation at 346 
nm, at emission 418 nm using a spectrophotometer Perkin Elmer LS-3, USA. Chinine 
sulphate (1 microgram/ml) was used to calibrate the instrument. Fluorescence was 
expressed as the relative fluorescence intensity in arbitrary units (A.U.). 
2.2.5 Determination of serum lipoperoxides 
Serum lipid peroxides were determined by iodine liberation spectrophotometrically at 365 
nm (Novaspec II, Pharmacia LKB, Biotech, SRN). The principle of this assay is based on the 
oxidative activity of lipid peroxides that will convert iodide to iodine. Iodine can then 
simply be measured by means of a photometer at 365 nm. Calibration curves were obtained 
using cumene hydroperoxide. A stoichiometric relationship was observed between the 
amount of organic peroxides assayed and the concentration of I3 produced (El-Saadani et al., 
1989).  
2.2.6 Determination of serum AOPP 
AOPP were determined in the plasma using the method previously devised by Witko-Sarsat 
et al. (1996), modified by Kalousova et al. (2002). Briefly, AOPP were measured by 
spectrophotometry on a reader (FP-901, Chemistry Analyser, Labsystems, Finland) and 
were calibrated with chloramine-T solutions that in the presence of potassium iodide absorb 
at 340 nm. In standard wells, 10 microliters of 1.16 M potassium iodide was added to 200 
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microliters of chloramine-T solution (0–100 micromol/l) followed by 20 microliters of acetic 
acid. In test wells, 200 microliters of plasma diluted 1:5 in PBS was placed to cell of 9 
channels, and 20 microliters of acetic acid was added. The absorbance of the reaction 
mixture is immediately read at 340 nm on the reader against a blank containing 200 
microliters of PBS, 10 microliters of potassium iodide, and 20 microliters of acetic acid. The 
chloramine-T absorbance at 340 nm being linear within the range of 0 to 100 micromol/l, 
AOPP concentrations were expressed as micromoles per liter of chloramine-T equivalents. 
2.2.7 Determination of TGF- beta1 
Quantitative detection of TGF- beta1 in serum was done by enzyme linked immunosorbent 
assay, using human TGF-beta1 ELISA-kit (BMS249/2, Bender MedSystem).  
Brief description of the method: into washed, with anti-TGF-beta1 precoated microplate 
were added prediluted (1:10) sera (100 microliters) and “HRP-Conjugate” (50 microliters) as 
a antihuman-TGF-beta1 monoclonal antibody and incubated for 4 hour on a rotator 
(100rpm). After microplate washing (3 times) “TMB Substrate Solution” (100 microliters) 
was added and was incubated for 10 minutes. Enzyme reaction was stopped by adding 
“Stop Solution” (100 microliters). The absorbance of each microwell was readed by 
HumaReader spectrophotometer (Human) using 450 nm wavelength. The TGF-beta1 
concentration was determined from standard curve prepared from seven TGF-beta1 
standard dilutions. Each sample and TGF-beta1 standard dilution were done in duplicate. 
2.2.8 Determination of serum soluble form of adhesion molecule VCAM-1  
For serum soluble form of VCAM-1 (sVCAM-1) estimating we used bead-based multiplex 
technology and Athena Multi-LyteTM Luminex 100 xMAP (multi-analyte profiling) 
analyser. We used RnD systems manufacturer kits: „Human Adhesion Molecule 
MultiAnalyte Profiling Base Kit“ and „Fluorokine® MAP Human sVCAM-1/CD106 Kit“. 
Analyte-specific antibodies are pre-coated onto color-coded microparticles. Microparticles, 
standards and samples are pipetted into wells and the immobilized antibodies bind the 
analytes of interest. After washing away any unbound substances, a biotinylated antibody 
cocktail specific to the analytes of interest are added to each well. Following a wash to 
remove any unbound biotinylated antibody, streptavidin-phycoerythrin conjugate 
(Streptavidin-PE), which binds to the captured biotinylated antibody, is added to each well. 
A final wash removes unbound Streptavidin-PE and the microparticles are resuspended in 
buffer and read using the Luminex analyzer. One laser is microparticle-specific and 
determines which analyte is being detected. The other laser determines the magnitude of the 
phycoerythrin-derived signal, which is in direct proportion to the amount of analyte bound 
(R&D Systems, Inc. 2010).  
2.2.9 Statistical analysis 
Shapiro-Wilk test was performed to the test the distribution of all continuous variables. The 
variables with normal distribution were compared by one way ANOVA test followed by 
Bonferroni´s post-test and the results was expressed as mean ± SD. Since the evaluated 
variables did not have normal distribution, we compared them with Kruskal–Wallis non-
parametric analysis of variance (ANOVA) followed by Bonferroni´s post-test and the results 
was expressed as median (1st quartile, 3rd quartile). The Fisher´s test was used to compare 
the subgroups in regard to diabetic retinopathy and other complications presence/absence. 
Pearson´s test with correlation coefficient r or Spearman´s one with Spearman's rank 
correlation coefficient R in case of small count of variables were then used to evaluate the 
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association between parameters described within the text, in all studied patients and in 
diabetic and non-diabetic subgroups. P values less than 0.05 were accepted as being 
statistically significant. All statistical analyses were carried out using Excel 2003, Origin 8 
and BioSTAT 2009. 
3. Results 
Clinical and biochemical characteristics of the patients with T1DM without and with 
diabetic complications and controls (CTRL) are reported in Table 1. 
 
  CTRL n T1DM -DC n T1DM +DC N 
Age (yrs.) 9.0(6.1,14.0) 26 14.4(12.4, 17.9)ab 20 16.4(15.1, 17.6)a 26 
DD (yrs.) - 0 6(5.5, 8.1)b 20 10.0(7.9, 12.9) 26 
HbA1cA (%) 5.0 ± 0.3 18 8.3 ± 1.4 ab 20 10.4 ± 1.4a 26 
FAM (mmol/l) 1.67 ± 0.31 24 2.64 ± 0.38 ab 20 3.06 ± 0.48a 26 
s-AGEs (A.U.) 54.9 ± 9.9 22 64.4 ± 10.1 ab 20 71.8 ± 11.6 24 
AOPP (micromol/l) 58.8(52.0, 71.8) 11 43.3(42.6, 60.4) 17 78.2(49.5, 114.6) 20 
LPO (nmol/ml) 100(88, 110) 10 106(105, 161) 19 127(109, 152)a 17 
TGF-beta1 (ng/ml) 3.30 ± 3.41 8 5.9 ± 4.14b 10 10.49 ± 4.55a 16 
VCAM-1 (ng/ml) 12.6 ± 3.7 15 17.1 ± 3.1 19 17.4 ± 3.3a 26 
a significant difference in comparison with CTRL 
b significant difference in comparison with +DC group T1DM 
Table 1. Clinical and biochemical characteristics of the patients with T1DM and controls 
As seen, HbA1c and FAM were significantly elevated in both diabetic groups in comparison 
with controls and also in +DC vs. –DC those. Serum AGEs were significantly elevated in 
+DC compared to –DC and also to controls, but the difference between –DC and controls 
was not significant. The levels of AOPP were evidently higher in +DC compared to controls, 
but the difference was not significant. The levels of LPO were significantly elevated in +DC 
vs. controls, the differences between both diabetic groups and between –DC vs. controls 
were not significant. The levels of TGF-beta1 similarly to s-AGEs were significantly elevated 
in +DC compared to –DC and also to controls, but the difference between –DC and controls 
was not significant (Fig. 1).  In terms of the VCAM-1 values, only between +DC and controls 
there were found significant difference there (Fig. 2). 
The levels of TGF-beta1 are significantly elevated in +DC compared to –DC (10.49 ± 4.55 vs. 
5.9 ± 4.14 ng/ml, p<0.05) and also to controls (10.49 ± 4.55 vs. 3.30 ± 3.41ng/ml, p<0.05), but 
the difference between –DC and controls (5.9 ± 4.14 vs. 3.30 ± 3.41ng/ml, p>0.05) was not 
statistically significant. 
3.1 The relationships between clinical and biochemical parameters  
3.1.1 The subgroup of patients with T1DM without diabetic complications 
The relationships characterized by Pearson´s correlation coefficient r or Spearman´s 
coefficient R between the parameters described within the text are reported in Table 2. As 
seen, we found significant linear correlations of FAM with HbA1cA (r=0.676), LPO with 
HbA1cP (r=-0.507) and AOPP (R=0.671). The relationship between LPO (y) and HbA1cP(x) 
is possible to describe by non-linear equation y=19x2-354x+1752 (R=0.632, R2=0.400, p<0.05). 
VCAM-1 significantly correlated with age (r=-0.478), HbA1cA (r=0.653, Fig. 3), HbA1cP 
(r=0.501) and with FAM (r=0.630, Fig. 4). 
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Fig. 1. Comparison of TGF-beta1 levels of patients with T1DM and controls 
 
 
Fig. 2. Comparison of VCAM-1 levels of patients with T1DM and controls 
The levels of VCAM-1 are significantly elevated in +DC compared to controls (17.4 ± 3.3 vs. 
12.6 ± 3.7 ng/ml, p<0.05). The values of VCAM-1 in –DC subgroup differ obviously from 
those in controls, but the difference is non statistically significant (17.1 ± 3.1 vs. 12.6 ± 3.7 
ng/ml, p>0.05). There are similar levels in both diabetic subgroups ((17.4 ± 3.3 vs. 17.1 ± 3.1 
ng/ml, p>>0.05). 
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Fig. 3. The linear correlation between VCAM-1 and HbA1cA 
 
 
DD 
(yrs.)
HbA1cA HbA1cP FAM s-AGEs AOPP  LPO  
TGF-
beta1  
VCAM-1  
Age (yrs.) 0.205 -0.267 -0.232 -0.328 -0.030 0.130† 0.334 0.406† -0.478∆ 
DD (yrs.) N 0.152 -0.008 0.326 -0.256 -0.193† -0.001 0.036† 0.089 
HbA1cA (%)  N 0.748∆ 0.676∆ 0.217 -0.298† -0.398 -0.588† 0.653∆ 
HbA1cP (%)   N 0.433 0.302 -0.400† -0.507∆ -0.042† 0.501∆ 
FAM 
(mmol/l) 
   N 0.134 0.081† -0.260 -0.224† 0.630∆ 
s-AGEs 
(A.U.) 
    N 0.197† 0.270 0.006 0.068 
AOPP 
(micromol/l) 
     N 0.671†∆ 0.477† -0.447† 
LPO 
(nmol/ml) 
      N 0.200† -0.404 
TGF-beta1 
(ng/ml) 
       N -0.578† 
Table 2. The relationships between the parameters in patients with T1DM without diabetic 
complications († R, ∆ p<0.05) 
In this subgroup LPO and VCAM-1 were in association also with other parameters, but 
those were not statistically significant. Non linear statistically significant relationship with 
regression line equation y=0.33x2 – 4.10x + 28.26 was found between VCAM-1(y) and 
HbA1cA(x) (R=0.694, R2=0.481, p<<0.05).  
3.1.2 The subgroup of patients with T1DM with diabetic complications 
The relationships characterized by Pearson´s correlation coefficient r or Spearman´s 
coefficient R between the parameters described within the text are reported in Table 3. 
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Fig. 4. The linear correlation between VCAM-1 and FAM 
 
  
DD 
(yrs.) 
HbA1cA HbA1cP FAM s-AGEs AOPP LPO  
TGF-
beta1  
VCAM-1  
Age (yrs.) 0.448∆ -0.295 -0.422∆ -0.023 -0.068 -0.165 -0.044† 0.541†∆ 0.067 
DD (yrs.) N -0.070 -0.110 -0.170 -0.069 -0.034 -0.297† 0.247† 0.009 
HbA1cA (%)  N 0.539∆ 0.581∆ 0.221 0.278 0.123† -0.429† 0.006 
HbA1cP (%)   N 0.3405 0.247 0.116 0.127† -0.679†∆ 0.291 
FAM 
(mmol/l) 
   N 0.479∆ 0.538∆ 0.471† -0.708†∆ 0.183 
s-AGEs 
(A.U.) 
    N 0.119† 0.125† -0.356† 0.432∆ 
AOPP 
(micromol/l) 
     N 0.355† -0.545† -0.026 
LPO 
(nmol/ml) 
      N -0.612† -0.174† 
TGF-beta1 
(ng/ml) 
       N -0.069† 
(† R, ∆ p<0.05) 
Table 3. The relationships between parameters described within the text  in patients with 
T1DM with diabetic complications  
As seen, in +DC subgroup we found significant correlations of FAM with HbA1cA 
(r=0.581), s-AGEs with FAM (r=0.479) and AOPP with FAM (r=0.538). LPO correlated with 
FAM (r=0.471), but this relation is not statistically significant (p=0.056). TGF-beta1 
correlated with age (R=0.541), HbA1cP (R=-0.679) and FAM (R=-0.708). Statistically 
significant moderate linear correlation was found between VCAM-1 and s-AGEs (r=0.432). 
Moderate relationships were found also between TGF-beta1 and oxidative stress 
parameters, but those were not statistically significant.  
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3.1.3 Controls 
As seen in Table 4, there were found moderate negative relation on the border of 
significance between AOPP and FAM (R=-0.627, p=0.05) and strong relation between AOPP 
and s-AGEs (R=0.855) in controls. TGF-beta1 was in statistically significant relation with age 
(R=-0.838) and s-AGEs (R=-0.757) and moderate, but not significant relationship was found 
with LPO (R=0.478). Slight relationship were found between VCAM-1 and FAM (R=0.366) 
and also between VCAM-1 and s-AGEs (R=0.267). 
 
 HbA1cA FAM  s-AGEs  AOPP  LPO  TGF-beta1  VCAM-1  
Age (yrs.) 0.354† -0.249 -0.008 0.193† 0.026† -0.838†∆ -0.052† 
HbA1cA (%) N 0.109† -0.133† -0.022† 0.189† -0.024† -0.068† 
FAM (mmol/l)  N -0.143 -0.627†■ -0.162† 0.276† 0.366† 
s-AGEs (A.U.)   N 0.855†∆ -0.382† -0.757†∆ 0.267† 
AOPP 
(micromol/l) 
   N -0.286† N 0.069† 
LPO (nmol/ml)     N 0.478† 0.037† 
TGF-beta1 
(ng/ml) 
     N 0.152† 
(† R, p<0.05, ■ p=0.05) 
Table 4. The relationships between the parameters in controls  
3.2 The parameters of glycative and oxidative stress, TGF-beta1 and VCAM-1 with 
regard to presence/absence of retinopathy and/or other complications 
We compared described parameters between subgroups with/without diabetic retinopathy. 
The results of Fisher´s post-test (p values) are reported in table 5.   
 
Subgroups FAM HbA1cA s-AGEs AOPP LPO TGF-beta1 VCAM-1 
DR vs. DR+O NS NS NS NS NS NA NS 
DR vs. ODC 0.055 NS 0.055 NS <0.05 <0.05 NS 
DR vs. -DC NS 0,01 NS NS NS <0.05 NS 
DR+O vs. ODC 0.052 NS 0,05 NS NS NA NS 
DR+O vs. -DC NS <0.05 NS NS NS NA NS 
ODC vs. -DC <0.05 <0.05 <0.05 NS NS NS NS 
(DR – having diabetic retinopathy only, DR+ODC – having diabetic retinopathy and another 
complications, ODC – having only other diabetic complications except diabetic retinopathy-DC – 
having no complications, NS – non-significant difference, NA – not available) 
Table 5. The differences in measured parameters between subgroups of patients with T1DM 
with regard to presence/absence of diabetic retinopathy and/or other (O) complications 
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FAM were significantly elevated in patients having diabetic complications only other than 
diabetic retinopathy compared to –DC (3.10(2.93, 3.54) vs. 2.54(2.42, 2.91) mmol/l, p<0.05, 
Fig. 5). HbA1c levels are elevated in patients having diabetic retinopathy against to –DC 
(9.8(9.6, 10.2) vs. (7.9(7.4, 9.1)%, p<0.05), in subgroup of patients having diabetic 
retinopathy with other complication/s compared to -DC (10.4(8.6, 11.2) vs. (7.9(7.4, 9.1) %, 
p<0.05, Fig.6) and also the subgroup of patients having diabetic complications only other 
than diabetic retinopathy compared to –DC (10.5(10.0, 11.1 vs. (7.9(7.4, 9.1) %, p<0.05, Fig. 
6). Serum AGEs were significantly higher in subgroup with only other diabetic 
complications than diabetic retinopathy compared to –DC one (74.8(71.2, 76.5) vs. 
61.9(58.9, 71.0) A.U., Fig. 7), and non-significantly higher in patients with retinopathy only 
than in those with others DC and also in patients with DR and another DC compared to 
ODC group, however, p-values were only slightly higher than 0.05 (Fig. 7). The values of 
LPO were significantly elevated in patients with complications other than retinopathy 
compared to those with retinopathy only (138(129, 165) vs. 101(93, 109) nmol/ml, Fig. 8). 
No significant differences were found between others in LPO. There were the significant 
differences between patients having only diabetic retinopathy vs. –DC in TGF-beta1 levels 
(14.17(13.32, 15.52) vs. 5.7(2.23, 8.71) ng/ml, p<0.05, Fig. 9) and also between subgroup of 
patients having only diabetic retinopathy and those having diabetic complications other 
than diabetic retinopathy (14.17(13.32, 15.52) vs. 9.05(5.29, 10.39) ng/ml, p=0.05, Fig. 9). 
Neither AOPP parameters nor VCAM-1 showed any significant differences between 
subgroups with regard to presence/absence diabetic retinopathy or other diabetic 
complications. 
 
 
Fig. 5. The values of FAM in subgroups of patients with T1DM with regard to diabetic 
retinopathy presence/absence (DR – having diabetic retinopathy only, DR+ODC – having 
diabetic retinopathy and another complications, ODC – having only other diabetic 
complications except diabetic retinopathy, -DC – having no complications) 
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Fig. 6. The values of HbA1c in subgroups of patients with T1DM with regard to diabetic 
retinopathy presence/absence (DR – having diabetic retinopathy only, DR+ODC – having 
diabetic retinopathy and another complications, ODC – having only other diabetic 
complications except diabetic retinopathy, -DC – having no complications) 
 
 
Fig. 7. The values of s-AGEs in subgroups of patients with T1DM with regard to diabetic 
retinopathy presence/absence (DR – having diabetic retinopathy only, DR+ODC – having 
diabetic retinopathy and another complications, ODC – having only other diabetic 
complications except diabetic retinopathy, -DC – having no complications) 
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Fig. 8. The values of LPO in subgroups of patients with T1DM with regard to diabetic 
retinopathy presence/absence (DR – having diabetic retinopathy only, DR+ODC – having 
diabetic retinopathy and another complications, ODC – having only other diabetic 
complications except diabetic retinopathy, -DC – having no complications) 
 
 
Fig. 9. The values of TGF-beta1 in subgroups of patients with T1DM with regard to diabetic 
retinopathy presence/absence (DR – having diabetic retinopathy only, ODC – having only 
other diabetic complications except diabetic retinopathy, -DC – having no complications)  
www.intechopen.com
 
Type 1 Diabetes – Complications, Pathogenesis, and Alternative Treatments 
 
16
4. Conclusion 
Our results suggest the relation of glycation and oxidation to profibrotic cytokines, vascular 
molecules and diabetic complications. Serum AGEs were connected with complications 
other than retinopathy more than just with retinopathy, nevertheless, some relation of 
retinopathy and s-AGEs was found (p-values were only slightly higher than 0.05). 
Lipoperoxides showed some relation to DR since higher in patients with retinopathy than in 
those with other DC, whereas AOPP did not show any relation to any DC. It seems that in 
our patients TGF-beta1 and VCAM-1 are linked with the development of DC, but only TGF-
beta1 showed some linkage to diabetic retinopathy.  
We ought to keep in mind the fact our investigation concerns the children and adolescents. 
Maybe the study of older patients with T1DM would show more, especially about VCAM-1 
and its relation to glycative and oxidative stress and consequently to development of 
retinopathy/other complications.  
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